Buradasınız

Anasayfa » Content

AMFOTERİSİN B'NİN NEDEN OLDUĞU HİPOPOTASEMİDE SPİRONOLAKTON KULLANIMI

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Treatment with spironolacton in hypokalemia caused by amphotericin B: Amphotericin B has been in clinical use for more than 35 years but stili remains the most effective dnıg for treatment of serious fungal infeetions. Its use has inereased in receht years as tîıe result of the rise in aggresive intehsive care support and inereased numbers of immunucompromised patients. Amphotericin B was adminİstered to our six patients suffering from acute leukemia and aplas-tic anemia. The indication of amphotericin B treatment in four patients at febril neutropenic stage was per-sistent fever in spite of antibiotic tretment, pneumonia caused by fungi in one, and hepatic fungal infectİon in one. Hypokalemia developed in ali patients after treatment with amphotericin B in spite of oral and parenteral potassium supplementatİon, and the level of potassium was found to be över 20 mmol in their 24-hour colleeted urİne. Hypokalemia was able to be cont-rolled by spirinolacton. It İs considered here that spirinolacton treatment can be administered in cases of hypokalemia caused by amphotericin B.
Bookmark/Search this post with
Abstract (Original Language): 
Amfoterİsin B, 35 yıldan uzun süredir klinik kullanımda bulunan, ciddi mantar infeksİyonla-rında cn etkili olan ilaçtır. Son yıllarda bağışıklığı baskılanmış hastaların sayısında vc yoğun ' bakım desteğinde anlamlı artış olması ile amfoterisin B kullanımı da artmıştır. Akut lökoz ve aplastik anemi tandan ile izlediğimiz 6 hastaya amfoterisin B (Fungizone) tedavisi uygulandı. Tedavi indikasyonu hastaların 4'ünde febril nötropenik dönemde antibiyotik tedavisine rağmen düşmeyen ateş, birinde mantar pnömonisİ, birinde karaciğerde mantar infeksiyonu saptanması idi. Amfoterisin B başlandıktan sonra hipopotasemi gelişen, parenteral ve oral potasyum verilmesine rağmen hipopotasemisi kontrol altına alınamayan 6 hastanın 24 saatlik idrarında potasyum düzeyi 20 mmol' den fazla bulundu. Bu hastalara spironolakton verilerek hipopotasemi kontrol altına alındı. Bu yazıda amfoterisin B'nİn neden olduğu hipopotaseminin tedavisinde spironolakton uygulanabileceği ifade edildi.
FULL TEXT (PDF): 
PDF icon arastirmax-amfoterisin-bnin-neden-oldugu-hipopotasemide-spironolakton-kullanimi.pdf
  • 4
435-439
  • Turkish

REFERENCES

References: 

1. Bernardo JF, Murakami S, Branch RA, Sabra R: Potassium depletion polentiates amphotericin-B-induced toxicity to renal tııbules. Ncphron; 70:235 (1995).
2. Camp MJ, Wingard JR, Cluire E, ct al: Efficacy of Iow-dose dopamine in preverıtLııs amphotericin B nephrotoxi-city in bone marrow transplant patients arıd leukemia patients. Antimicrob Agents Chemother; 42:3103 (1998).
3. Gulati M, Bajad S, Singh Si Ferdous AJ, Singh M:Deve-lopmcnt of liposomal amphotericin B formulation. J Mic-roencapsnl; 15:137 (1998).
4. Majer J, Duobek M, Vorlicek J: Must we rcaily fear toxi-city of conventional amphotericin B in oncoiogical patients?. Support Care Cancer; 7:51(1999).
5. Mota HF, Gastelbondo R, Saracho PN: Nephtoroxiciîy by amphDlricin B. Bol Med Hosp Infant Mex; 38:941(1981).
6. Sawaya BP, Briggs JP. Schnermann J: Ampholericin B nephrotoxicity:the adverse consequcnces of altered membrane pıoperlies. J Am Soc Nephro 1;6 (1995).

Thank you for copying data from http://www.arastirmax.com